Knowledge Library

AAV vectors are widely used in gene therapy, largely because they do not become integrated into the patient’s DNA and are safe from an immunogenicity perspective. AAVs also offer great versatility, with different targets possible using different serotypes. Relative to other vectors, AAVs are also generally produced at higher titers, which reduces costs. In addition, …Read More >

  Advancements in next-generation cell and gene therapies are fulfilling the promise of personalized medicine and attempting to cure and heal patients. Multiple approved products have been launched in global markets and the number of clinical trials continues to grow. Developing innovative advanced therapies is one of the biopharmaceutical industry’s greatest opportunities to dramatically improve …Read More >

WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmid for use in a wide variety of R&D, clinical, and  commercial bioprocessing applications, with an integrated platform of capabilities that allows for a seamless single-source approach …Read More >

In order to promote the public’s awareness of rare diseases and showcase WuXi AppTec’s positive social impact, on Aug. 20, we organized a 3-session webinar series on Spinal Muscular Atrophy, including a fireside chat between Dr. David Chang, CEO of WuXi ATU, and Paulo Fontoura, Global Head and SVP, Neuroscience and Rare Diseases Clinical Development …Read More >

Date: May 19, 2020 Time: 11 am EDT | 8 am PDT | 5 pm CEST For many years, the primary forms of cancer treatment have been chemotherapy, radiation, and surgery. An amazing breakthrough known as chimeric antigen receptor (CAR) T-cell therapy is being studied in the treatment of various types of cancer, including acute and …Read More >